News Agency
Men's Weekly

First Patient Dosed in QBiotics MSD Clinical Trial Collaboration for Unresectable Melanoma

  • Written by PR Newswire
  • First patient dosed with QBiotics' lead oncology molecule tigilanol tiglate in combination with KEYTRUDA® (pembrolizumab) in a clinical trial collaboration with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA)
  • The Phase Ib/IIa study will test the safety, optimal dose and tumour response of the combination in patients with...

Read more: First Patient Dosed in QBiotics MSD Clinical Trial Collaboration for Unresectable Melanoma

Insurance Industry Innovation Through VR Training

Australia's insurance industry, managing over $120 billion in annual premiums, operates at the intersection of financial services and human crisis. Insurance professionals must navigate emotionally charged situations daily, from claim denials to disaster responses. Leading insurers are now implementing best... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion